On May 6, 2023, SVB Securities released a research note announcing that they have increased Lantheus’ (NASDAQ:LNTH) target price from $120.00 to $127.00. This move comes as no surprise to many industry experts, who believe that the medical equipment provider is poised for continued growth and success.
Lantheus provides diagnostic imaging and nuclear medicine products that assist healthcare professionals with patient management and outcomes, particularly in the detection of cardiovascular disease. The company’s commitment to innovation has allowed it to remain at the forefront of the healthcare industry.
In February of this year, Lantheus reported earnings results which surpassed analyst expectations. The company’s EPS for the quarter was $1.28 compared to analysts’ consensus estimates of $0.87, representing an impressive beat of $0.41. Additionally, Lantheus generated revenue of $263.17 million during the quarter, exceeding analysts’ expected revenue of $244.61 million.
Lantheus’ success is further exemplified by its return on equity (ROE) of 51.60% and net margin of 3.00%. These figures demonstrate strong financial performance in a highly competitive industry.
Looking ahead, research analysts are optimistic about Lantheus’ future earnings potential with an estimated 4.65 earnings per share for the current year on average.
SVB Securities’ increase in Lantheus’ target price represents a potential upside for investors looking to capitalize on the company’s continued growth trajectory. At 31.67% higher than its current price level, Lantheus holds significant potential for investors seeking high returns on investment.
In conclusion, Lantheus Holdings Inc.’s innovative approach towards developing healthcare solutions has resulted in record-breaking earnings results and financial performance over time making it a promising investment opportunity for those interested in investsments offering strategic potential given their growth tracking trends over time increasing stakeholder profitabiity.
Lantheus Holdings Receives Positive Analyst Feedback, Shares Rise
Lantheus Holdings, Inc. (NASDAQ: LNTH) has been receiving positive feedback from analysts recently, causing shares to rise steadily. Several other analysts have raised their price target on Lantheus stock with buy ratings. One report by Mizuho raised its target price from $115.00 to $125.00 on Friday, while StockNews.com upgraded its rating from hold to buy on Tuesday.
JMP Securities also increased its Lantheus price target from $120.00 to $130.00, and Truist Financial lifted its price range for the stock from $115.00 to $125.00 later that day.
The company presently carries an average consensus rating of “Buy,” according to Bloomberg, based on seven buy ratings in total and an average target price of $117.43.
On Friday, May 6, Nasdaq LNTH traded up at mid-day at $96.45 with 373,975 shares being exchanged compared to an average volume of 1,021,837 shares per day.
Lantheus develops diagnostic imaging and nuclear medicine products globally that support healthcare professionals in patient management and outcomes while helping clinicians detect cardiovascular disease better. It operates within the U.S and International geographical segments.
Also worth noting is a transaction made by Andrea Sabens who sold 386 shares of the firm’s stock on April 17th for an average price of $88.67 each earning her a total of $34,226.62 which she disclosed via SEC filing earlier this month along with the sale of more stocks by corporate insiders over the last quarter totaling about 235905 shares worth around
$17,85698011 which represents approximately 1.50% of the stock currently owned by corporate insiders
There has been recent activity regarding institutional investment in Lantheus as well with CWM LLC growing its stake in LNTH shares by 82.% during Q3 last year. Wipfli Financial Advisors LLC and Wolverine Asset Management LLC acquired new stakes in the company during Q3 and Q4 respectively, while National Bank of Canada FI increased its holdings on Lantheus during Q1 earlier this year by 35.7%.